Benitec Biopharma Inc. (BNTC) announced continued durable improvements in swallowing following administration of the low-dose of BB-301 in the study's first two subjects treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study in Oculopharyngeal Muscular Dystrophy or OPMD.
According to the company, two Subjects received the lowest dose of gene therapy BB-301 (1.2e13 vg/subject), with no significant adverse events reported. At baseline, Subject 1 exhibited more severe dysphagic symptoms compared to Subject 2, as assessed by pre-dose SSQ and TPR results. However, both subjects experienced significant clinical benefits, as indicated by their post-dose SSQ scores and TPR results.
The SSQ Total Scores and Sub-Scores demonstrated a strong correlation with the VFSS TPR results. Subject 1 showed clinically meaningful improvements in the post-dose SSQ Total Score and Sub-Scores by Day 270, which were driven by corresponding reductions in VFSS TPR values. Meanwhile, Subject 2 achieved clinically meaningful improvements in the post-dose SSQ Total Score and Sub-Scores by Day 180, reaching a score indicative of a normal swallowing profile, primarily due to a reduction in the frequency of pathologic low-volume sequential swallows.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.